Combination therapy with radiation shows promise in treating glioblastoma

In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve the overall survival in mice with glioblastoma. Glioblastoma is one of the deadliest and most difficult-to-treat brain tumors. Researchers found the triple combination extended the median survival 4-fold compared to radiation alone.

UCLA researchers previously reported that the first-generation dopamine receptor antagonist trifluoperazine in combination with radiation prolonged survival in mouse models of glioblastoma, but ultimately, the mice become resistant to the therapy. To help overcome this resistance, the team used quetiapine, a second-generation dopamine receptor antagonist, which not only enhanced the efficacy of radiotherapy in glioblastoma but also generated a metabolic vulnerability in the lipid homeostasis. The discovery that the combination induced the cholesterol biosynthesis pathway allowed the team to target this process with statins.

The team tested the approach using patient-derived glioblastoma lines provided by the Biospecimen and Pathology Core of the UCLA SPORE in Brain Cancer. Quetiapine was identified in a screen of dopamine receptor antagonists for their ability to prevent phenotype conversion of non-tumorigenic glioblastoma cells into radiation-induced glioma initiating cells. Atorvastatin (Lipitor) was selected because of its known ability to cross the blood-brain-barrier.

While radiation alone prolongs survival of glioblastoma to some extent, attempts to enhance the treatment have not been successful. The results of the study provide evidence that using a dopamine receptor antagonist in combination with Atorvastatin and radiation may help extend the survival for people with glioblastoma. The combination therapy also includes FDA-approved drugs that can rapidly be translated into a clinical trial.